Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Engulfment and cell motility protein 3 is a member of the ELMO protein family, acting as an adaptor that regulates cellular movement and actin cytoskeletal dynamics through the activation of Rac1 via interaction with DOCK-family GEFs (guanine nucleotide exchange factors)[1][2][4][6]. It is homologous to CED-12 in C. elegans and is involved in processes such as phagocytosis of apoptotic cells and cell migration[1][2][4][6]. In human physiology, ELMO3 expression is tightly regulated and, when upregulated, can contribute to cancer cell migration, invasion, and proliferation through enhanced actin polymerization[3][6]. Although less studied than its paralogs ELMO1 and ELMO2, ELMO3 has been implicated as a pathogenic factor in both oncogenic processes and neurodevelopmental disorders caused by biallelic mutations[2][3][6]. There are currently no known drugs or mechanisms targeting ELMO3 directly, nor is it established as a therapeutic target; instead, it is regarded as a critical signalling adaptor influencing cell morphology and pathogenesis[2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Engulfment and cell motility protein 3 (ELMO3).